PURPOSE: Pompe disease (PD) is a progressive metabolic myopathy for which the only available treatment is alglucosidase alfa (Myozyme®). Enzyme replacement therapy (ERT) has improved ventilator-free survival, and cardiac and motor functions in patients with infantile PD. However, for an adequate response to occur, a large amount of enzymes must be infused. In some patients, this may be problematic due to infusion-associated reactions (IARs) occurring in approximately 50% of patients receiving alglucosidase alfa infusions. Whilst the majority of these reactions are mild, life threatening hypersensitivity reactions may occur in some patients. In these patients desensitization is indicated to enable continued ERT safely. Infants and young children with PD and significant infusion reactions pose unique management challenges because of their young age, limited communication skills, variable presentation and underlying cardiomyopathy. METHODS/ SUBJECTS: In 2 patients with PD who experienced significant ERT-related reactions: an infant (IgE positive) and a young child (IgE negative), we implemented a desensitization protocol, that started by administering a reduced dose of alglucosidase alfa (10 mg/kg weekly) instead of the standard (20 mg/kg bi-weekly) using serial micro-dilutions that were individually prepared and delivered in a highly regulated manner based on patients' clinical manifestations and tolerance. RESULTS: Successful desensitization was achieved in both patients, allowing them to eventually continue to receive the full dose of ERT safely. CONCLUSION: Therapeutic demands in infants and young children with PD need to be tailored according to the patient presentation, and underlying cardiac and fluid-volume status. Desensitization allowed both patients to continue alglucosidase alfa treatment at the recommended dose without prolonged interruption of therapy, or further reactions.
PURPOSE: Pompe disease (PD) is a progressive metabolic myopathy for which the only available treatment is alglucosidase alfa (Myozyme®). Enzyme replacement therapy (ERT) has improved ventilator-free survival, and cardiac and motor functions in patients with infantile PD. However, for an adequate response to occur, a large amount of enzymes must be infused. In some patients, this may be problematic due to infusion-associated reactions (IARs) occurring in approximately 50% of patients receiving alglucosidase alfa infusions. Whilst the majority of these reactions are mild, life threatening hypersensitivity reactions may occur in some patients. In these patients desensitization is indicated to enable continued ERT safely. Infants and young children with PD and significant infusion reactions pose unique management challenges because of their young age, limited communication skills, variable presentation and underlying cardiomyopathy. METHODS/ SUBJECTS: In 2 patients with PD who experienced significant ERT-related reactions: an infant (IgE positive) and a young child (IgE negative), we implemented a desensitization protocol, that started by administering a reduced dose of alglucosidase alfa (10 mg/kg weekly) instead of the standard (20 mg/kg bi-weekly) using serial micro-dilutions that were individually prepared and delivered in a highly regulated manner based on patients' clinical manifestations and tolerance. RESULTS: Successful desensitization was achieved in both patients, allowing them to eventually continue to receive the full dose of ERT safely. CONCLUSION: Therapeutic demands in infants and young children with PD need to be tailored according to the patient presentation, and underlying cardiac and fluid-volume status. Desensitization allowed both patients to continue alglucosidase alfa treatment at the recommended dose without prolonged interruption of therapy, or further reactions.
Authors: J R Cernadas; K Brockow; A Romano; W Aberer; M J Torres; A Bircher; P Campi; M L Sanz; M Castells; P Demoly; W J Pichler Journal: Allergy Date: 2010-08-17 Impact factor: 13.146
Authors: Shawn E Lipinski; Michael J Lipinski; Autumn Burnette; Thomas A Platts-Mills; William G Wilson Journal: Mol Genet Metab Date: 2009-07-07 Impact factor: 4.797
Authors: Mariana C Castells; Nichole M Tennant; David E Sloane; F Ida Hsu; Nora A Barrett; David I Hong; Tanya M Laidlaw; Henry J Legere; Samridhi N Nallamshetty; Ross I Palis; Jayanti J Rao; Suzanne T Berlin; Susana M Campos; Ursula A Matulonis Journal: J Allergy Clin Immunol Date: 2008-05-27 Impact factor: 10.793
Authors: James E Wraith; Lorne A Clarke; Michael Beck; Edwin H Kolodny; Gregory M Pastores; Joseph Muenzer; David M Rapoport; Kenneth I Berger; Stuart J Swiedler; Emil D Kakkis; Tanja Braakman; Elenie Chadbourne; Karen Walton-Bowen; Gerald F Cox Journal: J Pediatr Date: 2004-05 Impact factor: 4.406
Authors: William R Wilcox; Maryam Banikazemi; Nathalie Guffon; Stephen Waldek; Philip Lee; Gabor E Linthorst; Robert J Desnick; Dominique P Germain Journal: Am J Hum Genet Date: 2004-05-20 Impact factor: 11.025
Authors: Diego G Peroni; Lydia Pescollderungg; Giorgio L Piacentini; Walburga Cassar; Attilio L Boner Journal: J Pediatr Date: 2009-12 Impact factor: 4.406
Authors: David Bodensteiner; C Ronald Scott; Katherine B Sims; Gillian M Shepherd; Rebecca D Cintron; Dominique P Germain Journal: Genet Med Date: 2008-05 Impact factor: 8.822
Authors: Mary G Prieve; Pierrot Harvie; Sean D Monahan; Debashish Roy; Allen G Li; Teri L Blevins; Amber E Paschal; Matt Waldheim; Eric C Bell; Anna Galperin; Jean-Rene Ella-Menye; Michael E Houston Journal: Mol Ther Date: 2018-01-04 Impact factor: 11.454